Zurich-Schlieren, Apil 18, 2018. At today’s Annual General Meeting of Molecular Partners AG (SIX: MOLN), the shareholders of the company approved all motions proposed by the Board of Directors with a large majority and elected William (Bill) Burns as new Chairman of the Board.

Research & Development: MP0250 in multiple myeloma (MM): Promising initial safety and efficacy data from the ongoing phase 2 study of MP0250 reconfirmed with updated data presented at the European Myeloma Network Meeting  in Turin on April 21 MP0250 in EGFR-mutated Non-Small Cell Lung Cancer (EGFR

Zurich-Schlieren, Apil 11, 2018.  Molecular Partners AG (ticker: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies*, announced today that Molecular Partners and AstraZeneca (LON: AZN) will collaborate on Molecular Partners’ ongoing phase

Zurich-Schlieren, Apil 05, 2018.  Molecular Partners AG (ticker: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies*, today announced that new pre-clinical data from two of its pipeline candidates, MP0310 and its lead proprietary oncology

Zurich-Schlieren, March 21, 2018.  Molecular Partners AG (ticker: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies*, today published the invitation to the Annual General Meeting 2018. The Annual General Meeting will be held on Wednesday,

Zurich-Schlieren, March 16, 2018.  Molecular Partners AG (ticker: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies*, today published its audited Financial Results for 2017 and the company’s 2017 Annual Report.

Zurich-Schlieren, March 06, 2018.  Molecular Partners AG (ticker: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies*, today announced that it will present at the Cowen and Company 38th Annual Healthcare Conference on Tuesday, March 13, 2018

Zurich-Schlieren, February 19, 2018.  Molecular Partners AG (ticker: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies*, today announced that Allergan has exercised the third option to develop and commercialize DARPin® product candidates

Research & Development: MP0250 in multiple myeloma (MM): Promising initial safety and efficacy data from the ongoing phase 2 study of MP0250 MP0250 in EGFR-mutated non-small cell lung cancer (EGFR mut NSCLC): Following FDA approval of IND for phase 1b/2 study on track to dose first patient in Q1

Zurich-Schlieren, January 08, 2018.  Molecular Partners AG (ticker: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies*, today announced initial safety and efficacy data from its ongoing phase 2 study of MP0250 in multiple myeloma (MM).